No profile data available.
Xeris Biopharma Holdings, Inc. (XERS) is a healthcare company in the additional hormone and metabolic drugs industry, based in Chicago, United States, with about 435 full-time employees.
It reported revenue of $291.85 million for fiscal year 2025, up 43.7% from fiscal year 2024, and net income of $554,000. Its market capitalization was $1.91 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois.
Xeris Biopharma reported $291.85 million in revenue for fiscal year 2025, up 43.7% from $203.07 million in fiscal year 2024.
$1.91 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (additional hormone and metabolic drugs) include BridgeBio Pharma, Inc. (BBIO), Amylyx Pharmaceuticals, Inc. (AMLX), MBX Biosciences, Inc. (MBX), Eton Pharmaceuticals, Inc. (ETON).